Bordeaux, January 17, 2024 – 6:00 p.m. CET – Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces the strengthening of its management team with the appointment of Arsène Guekam to the position of Chief Corporate Development Officer (CDO).
With more than 15 years of experience in the field of Health (biotech/medtech) and the financial sector, Arsène Guekam brings to Aelis Farma essential expertise in these areas. A graduate in Pharmacy and the Grandes Ecoles program at EM Lyon (finance option), Arsène held key positions as a financial analyst at several renowned brokers such as Oddo BHF, CM-CIC Securities or Crédit Lyonnais Small Caps. Before joining Aelis Farma, Arsène was Senior Analyst, Head of Biotech Research in the Kepler Cheuvreux office and then Co-Head of Healthcare Research.
To receive all AELIS FARMA financial information in real time, request it by email to [email protected]. Your registration will be immediate.